Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron Add-on to Tamsulosin for OAB in Men with BPH
NCT02656173Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial in overactive bladder (OAB) comparing Mirabegron + Tamsulosin with Placebo + Tamsulosin (2 arms). Primary endpoint: Change From Baseline to End of Treatment in Mean Number of Micturitions Per 24 Hours at 12 weeks. Started Jan 2016; status: completed.
02
Drugs
mirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02656173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02656173.